";s:4:"text";s:4313:" Metoprolol Succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure.
It is freely soluble in water and soluble in methanol.Inactive ingredients: acetyl tributyl citrate, colloidal silicon dioxide, croscarmellose sodium, ethyl cellulose, hydrogenated vegetable oil, hydroxypropyl cellulose, hypromellose, methylene chloride, microcrystalline cellulose, polyethylene glycol 6000, sodium stearyl fumarate, talc and titanium dioxide.Hypertension: The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. Abrupt withdrawal of beta-blockade may precipitate a thyroid storm.While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat an allergic reaction.Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.Because of significant inotropic and chronotropic effects in patients treated with beta-blockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly.The following adverse reactions are described elsewhere in labeling:Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. At steady state the average bioavailability of metoprolol following administration of Metoprolol Succinate extended-release, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol. If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Succinate extended-release [see PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Metoprolol Succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.Long-term studies in animals have been conducted to evaluate the carcinogenic potential of metoprolol tartrate. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Concomitant use with beta-blockers can increase the risk of bradycardia.If clonidine and a beta-blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. Beta-blocker overdose may result in significant resistance to resuscitation with adrenergic agents, including beta-agonists. Metoprolol is a racemic mixture of R- and S- enantiomers, and is primarily metabolized by CYP2D6. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.